[go: up one dir, main page]

EP1599214A4 - Methodes et compositions destinees a traiter le cancer du col uterin - Google Patents

Methodes et compositions destinees a traiter le cancer du col uterin

Info

Publication number
EP1599214A4
EP1599214A4 EP04715735A EP04715735A EP1599214A4 EP 1599214 A4 EP1599214 A4 EP 1599214A4 EP 04715735 A EP04715735 A EP 04715735A EP 04715735 A EP04715735 A EP 04715735A EP 1599214 A4 EP1599214 A4 EP 1599214A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
cervical cancer
treating cervical
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04715735A
Other languages
German (de)
English (en)
Other versions
EP1599214A2 (fr
Inventor
Peter S Lu
Christoph Peter Bagowski
Johannes Schweizer
Chamorro Somoza Diaz-Sarmiento
Jonathan D Garman
Michael P Belmares
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arbor Vita Corp
Original Assignee
Arbor Vita Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/630,590 external-priority patent/US7312041B2/en
Application filed by Arbor Vita Corp filed Critical Arbor Vita Corp
Publication of EP1599214A2 publication Critical patent/EP1599214A2/fr
Publication of EP1599214A4 publication Critical patent/EP1599214A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP04715735A 2003-02-27 2004-02-27 Methodes et compositions destinees a traiter le cancer du col uterin Withdrawn EP1599214A4 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US45046403P 2003-02-27 2003-02-27
US450464P 2003-02-27
US49009403P 2003-07-25 2003-07-25
US490094P 2003-07-25
US630590 2003-07-29
US10/630,590 US7312041B2 (en) 2001-02-16 2003-07-29 Methods of diagnosing cervical cancer
PCT/US2004/006001 WO2004076646A2 (fr) 2003-02-27 2004-02-27 Methodes et compositions destinees a traiter le cancer du col uterin

Publications (2)

Publication Number Publication Date
EP1599214A2 EP1599214A2 (fr) 2005-11-30
EP1599214A4 true EP1599214A4 (fr) 2006-06-21

Family

ID=32931336

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04715735A Withdrawn EP1599214A4 (fr) 2003-02-27 2004-02-27 Methodes et compositions destinees a traiter le cancer du col uterin

Country Status (2)

Country Link
EP (1) EP1599214A4 (fr)
WO (1) WO2004076646A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6942981B1 (en) 1999-05-14 2005-09-13 Arbor Vita Corporation Method of determining interactions with PDZ-domain polypeptides
WO2010102070A1 (fr) * 2009-03-03 2010-09-10 Arbor Vita Corporation Procédés de traitement d'un cancer associé aux hpv au moyen d'inhibiteurs de jnk
WO2015097268A1 (fr) * 2013-12-23 2015-07-02 Universite De Strasbourg Construction chimérique pour le diagnostic et le traitement des cancers induits par le papillomavirus
WO2020214957A1 (fr) 2019-04-19 2020-10-22 Tcrcure Biopharma Corp. Anticorps anti-pd-1 et leurs utilisations
WO2021155518A1 (fr) * 2020-02-05 2021-08-12 Tcrcure Biopharma Corp Récepteurs de lymphocytes t anti-hpv et cellules modifiées

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003014303A2 (fr) * 2001-08-03 2003-02-20 Arbor Vita Corporation Interactions moleculaires dans les cellules

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4108846A (en) 1977-02-01 1978-08-22 Hoffmann-La Roche Inc. Solid phase synthesis with base N alpha-protecting group cleavage
HK1040418A1 (zh) * 1998-11-17 2002-06-07 Deltagen Proteomics, Inc. 确认与细胞表型有关的多肽靶的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003014303A2 (fr) * 2001-08-03 2003-02-20 Arbor Vita Corporation Interactions moleculaires dans les cellules

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2004076646A2 *
THOMAS MIRANDA ET AL: "Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation", ONCOGENE, vol. 21, no. 33, 1 August 2002 (2002-08-01), pages 5088 - 5096, XP002380805, ISSN: 0950-9232 *

Also Published As

Publication number Publication date
EP1599214A2 (fr) 2005-11-30
WO2004076646A2 (fr) 2004-09-10
WO2004076646A3 (fr) 2005-06-09

Similar Documents

Publication Publication Date Title
EP2671581B8 (fr) Compositions et procédés pour le traitement du cancer
IL172194A0 (en) Methods and compositions for treating amyloid-related diseases
AU2003284242A8 (en) Methods and compositions for use in treating cancer
GB2423928B (en) Methods and compositions for treating pain
EP1468118A4 (fr) Procedes et compositions pour le traitement du cancer
AU2003293194A8 (en) Compositions and methods for treating prostate cancer
AU2003230750A1 (en) Compositions and methods for treating cancer
ZA200600384B (en) Compositions and methods for increasing bone mineralization
GB2421434B (en) Compositions And Methods For Treating Gynaecological Disorders
EP1572118A4 (fr) Methodes et compositions de traitement de cancer au moyen des genes 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883
IL176919A0 (en) Methods and compositions for treating cancer
EP1596806A4 (fr) Compositions et methodes permettant de traiter le cancer au moyen de igsf9 et de liv-1
AU2003219160A1 (en) Methods and compositions for the treatment of cancer
IL172294A0 (en) Methods and compositions for interferon therapy
IL166062A0 (en) Compositions and methods for therapeutic treatment
AU2003298708A8 (en) Gpc99 and gpc99a: methods and compositions for treating cancer
EP1599214A4 (fr) Methodes et compositions destinees a traiter le cancer du col uterin
AU2003225461A8 (en) Composition and method for supporting cancer treatments
EP1587405A4 (fr) Nouvelles compositions et procedes de traitement du cancer
AU2003275433A8 (en) Compositions and methods for treating pain
EP1684795A4 (fr) Procedes et agents pour le traitement du cancer
AU2003295604A8 (en) Gpc15: methods and compositions for treating cancer
AU2002360454A8 (en) Methods and compositions for treating cancer
IL163878A0 (en) Compositions and methods for treating mdma-inducedtoxicity
HK1087345A (en) Compositions and methods for treating cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050916

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20060524

17Q First examination report despatched

Effective date: 20070718

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100126